Moderna secures EU COVID-19 vaccine supply deal

Published 24/01/2025, 12:32
© Reuters

CAMBRIDGE, MA - Moderna , Inc. (NASDAQ:MRNA) has secured a tender to supply its mRNA COVID-19 vaccine to the European Union, including additional countries Norway and North Macedonia. The agreement, announced today, allows 17 participating nations to procure Moderna's vaccine over the next four years.

Chantal Friebertshäuser, Moderna's Senior Vice President for Europe & Middle-East, emphasized the importance of diverse vaccine supply and the availability of pre-filled syringe formats. The latter is expected to streamline vaccination processes and reduce administration errors.

The European Commission authorized an updated version of Moderna's vaccine, Spikevax, in September 2024, which targets the SARS-CoV-2 variant JN.1. The approval extends to individuals aged six months and older.

Moderna, a pioneer in mRNA therapeutics and vaccines, has been at the forefront of mRNA technology, contributing significantly to the rapid development and production of COVID-19 vaccines. The company's mRNA platform is also being utilized to develop treatments for a range of other diseases.

This agreement marks a continuation of Moderna's commitment to supporting global health security through its innovative mRNA medicines. The information disclosed in this article is based on a press release statement from Moderna, Inc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.